Connection

Donald Castell to Proton Pump Inhibitors

Back to Details
This is a "connection" page, showing publications Donald Castell has written about Proton Pump Inhibitors.
Donald Castell
Connection Strength
9.428
Proton Pump Inhibitors
  1. The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus. Drugs. 2017 Apr; 77(5):547-561.
    View in: PubMed
    Score: 0.527
  2. The Role of Acid Suppression in Barrett's Esophagus. Am J Med. 2017 May; 130(5):525-529.
    View in: PubMed
    Score: 0.521
  3. Cough and Throat Clearing: Atypical GERD Symptoms or Not GERD at All? J Clin Gastroenterol. 2016 May-Jun; 50(5):e50-4.
    View in: PubMed
    Score: 0.495
  4. Concomitant Administration of a Histamine2 Receptor Antagonist and Proton Pump Inhibitor Enhances Gastric Acid Suppression. Pharmacotherapy. 2015 Dec; 35(12):1124-9.
    View in: PubMed
    Score: 0.481
  5. Monitoring for GE Reflux: Is Normal the New Normal? Dig Dis Sci. 2015 May; 60(5):1118-9.
    View in: PubMed
    Score: 0.462
  6. Twice-daily proton pump inhibitor therapy does not decrease the frequency of reflux episodes during nocturnal recumbency in patients with refractory GERD: analysis of 200 patients using multichannel intraluminal impedance-pH testing. Dis Esophagus. 2012 Nov-Dec; 25(8):682-6.
    View in: PubMed
    Score: 0.369
  7. Comparison of reflux frequency during prolonged multichannel intraluminal impedance and pH monitoring on and off acid suppression therapy. J Clin Gastroenterol. 2009 Oct; 43(9):816-20.
    View in: PubMed
    Score: 0.313
  8. Further comment on proton pump inhibitor failures. Clin Gastroenterol Hepatol. 2009 Mar; 7(3):363.
    View in: PubMed
    Score: 0.289
  9. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough. J Clin Gastroenterol. 2008 Jul; 42(6):676-9.
    View in: PubMed
    Score: 0.287
  10. Characteristics of symptomatic reflux episodes on Acid suppressive therapy. Am J Gastroenterol. 2008 May; 103(5):1090-6.
    View in: PubMed
    Score: 0.284
  11. An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring. Clin Gastroenterol Hepatol. 2008 May; 6(5):521-4.
    View in: PubMed
    Score: 0.282
  12. Comparison between the combined analysis and the DeMeester Score to predict response to PPI therapy. J Clin Gastroenterol. 2006 Aug; 40(7):602-5.
    View in: PubMed
    Score: 0.252
  13. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006 Oct; 55(10):1398-402.
    View in: PubMed
    Score: 0.246
  14. Do we need to rethink fundoplication for patients who have failed proton-pump-inhibitor therapy? Nat Clin Pract Gastroenterol Hepatol. 2006 Jan; 3(1):2-3.
    View in: PubMed
    Score: 0.242
  15. Review of immediate-release omeprazole for the treatment of gastric acid-related disorders. Expert Opin Pharmacother. 2005 Nov; 6(14):2501-10.
    View in: PubMed
    Score: 0.239
  16. Esophageal pH monitoring on PPI therapy: removing the blinders. Am J Gastroenterol. 2005 Aug; 100(8):1893-4; author reply 1894.
    View in: PubMed
    Score: 0.235
  17. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus. 2005; 18(6):370-3.
    View in: PubMed
    Score: 0.226
  18. Nocturnal acid breakthrough: pH, drugs and bugs. Eur J Gastroenterol Hepatol. 2004 May; 16(5):441-3.
    View in: PubMed
    Score: 0.215
  19. Nocturnal acid breakthrough in perspective: let's not throw out the baby with the bath water. Am J Gastroenterol. 2003 Mar; 98(3):517-8.
    View in: PubMed
    Score: 0.199
  20. Does acid suppression alter progression in Barrett's esophagus? Am J Gastroenterol. 2003 Jan; 98(1):213-4; author reply 214.
    View in: PubMed
    Score: 0.196
  21. Control of intragastric pH with omeprazole 20 mg, omeprazole 40 mg and lansoprazole 30 mg. Aliment Pharmacol Ther. 2001 May; 15(5):647-52.
    View in: PubMed
    Score: 0.175
  22. Maximal acid reflux control for Barrett's oesophagus: feasible and effective. Aliment Pharmacol Ther. 2001 Apr; 15(4):519-24.
    View in: PubMed
    Score: 0.174
  23. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. 2000 Oct; 14(10):1267-72.
    View in: PubMed
    Score: 0.168
  24. Oesophageal motility defects associated with nocturnal gastro-oesophageal reflux on proton pump inhibitors. Aliment Pharmacol Ther. 1999 Nov; 13(11):1467-71.
    View in: PubMed
    Score: 0.158
  25. Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn. N Engl J Med. 2019 10 17; 381(16):1513-1523.
    View in: PubMed
    Score: 0.157
  26. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther. 1998 Dec; 12(12):1231-4.
    View in: PubMed
    Score: 0.148
  27. Alternative therapies for GERD: a way to personalized antireflux surgery. Ann N Y Acad Sci. 2018 12; 1434(1):360-369.
    View in: PubMed
    Score: 0.142
  28. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol. 1998 May; 93(5):763-7.
    View in: PubMed
    Score: 0.142
  29. Management options for patients with GERD and persistent symptoms on proton pump inhibitors: recommendations from an expert panel. Am J Gastroenterol. 2018 07; 113(7):980-986.
    View in: PubMed
    Score: 0.142
  30. Distal Esophageal Spasm: A Review. Am J Med. 2018 09; 131(9):1034-1040.
    View in: PubMed
    Score: 0.141
  31. Symptom Index or Symptom Association Probability?: A Closer Look at Symptom Association in Suspected GERD Patients. J Clin Gastroenterol. 2018 Jan; 52(1):e7-e10.
    View in: PubMed
    Score: 0.139
  32. Acid control and regression of Barrett's esophagus: is the glass half full or half empty? Am J Gastroenterol. 1997 Dec; 92(12):2329-30.
    View in: PubMed
    Score: 0.138
  33. Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux. Dig Dis Sci. 1997 Oct; 42(10):2138-45.
    View in: PubMed
    Score: 0.136
  34. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol. 1996 Sep; 91(9):1749-57.
    View in: PubMed
    Score: 0.127
  35. Omeprazole works best when used properly. Eur J Gastroenterol Hepatol. 1996 May; 8(5):413-4.
    View in: PubMed
    Score: 0.124
  36. Extraesophageal gastroesophageal reflux disease (GERD) symptoms are not more frequently associated with proximal esophageal reflux than typical GERD symptoms. Dis Esophagus. 2012 Nov-Dec; 25(8):678-81.
    View in: PubMed
    Score: 0.092
  37. The changing paradigm of GERD. Curr Gastroenterol Rep. 2007 Dec; 9(6):441-2.
    View in: PubMed
    Score: 0.069
  38. Combined multichannel intraluminal impedance-pH monitoring to select patients with persistent gastro-oesophageal reflux for laparoscopic Nissen fundoplication. Br J Surg. 2006 Dec; 93(12):1483-7.
    View in: PubMed
    Score: 0.064
  39. Review article: oesophageal spasm - diagnosis and management. Aliment Pharmacol Ther. 2006 May 15; 23(10):1393-402.
    View in: PubMed
    Score: 0.062
  40. Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers. Clin Ther. 2006 May; 28(5):725-33.
    View in: PubMed
    Score: 0.062
  41. Diagnosis of laryngopharyngeal reflux. Curr Opin Otolaryngol Head Neck Surg. 2004 Jun; 12(3):174-9.
    View in: PubMed
    Score: 0.054
  42. Gastroesophageal reflux disease: natural history and long-term medical and surgical outcomes. Clin Cornerstone. 2003; 5(4):51-7; discussion 58-60.
    View in: PubMed
    Score: 0.049
  43. Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers. Aliment Pharmacol Ther. 2002 Apr; 16(4):829-36.
    View in: PubMed
    Score: 0.047
  44. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther. 2001 Sep; 15(9):1351-6.
    View in: PubMed
    Score: 0.045
  45. Medical therapy for gastroesophageal reflux disease. Mayo Clin Proc. 2001 Jan; 76(1):102-6.
    View in: PubMed
    Score: 0.043
  46. Medical therapy of supraesophageal gastroesophageal reflux disease. Am J Med. 2000 Mar 06; 108 Suppl 4a:170S-177S.
    View in: PubMed
    Score: 0.040
  47. Medical therapy. Management of the refractory patient. Gastroenterol Clin North Am. 1999 Dec; 28(4):847-60.
    View in: PubMed
    Score: 0.040
  48. Barrett's esophagus: continuing questions and controversy. Gastrointest Endosc. 1999 Mar; 49(3 Pt 2):S5-8.
    View in: PubMed
    Score: 0.038
  49. Prolonged ambulatory pH monitoring in patients with persistent gastroesophageal reflux disease symptoms: testing while on therapy identifies the need for more aggressive anti-reflux therapy. Am J Gastroenterol. 1996 Oct; 91(10):2110-3.
    View in: PubMed
    Score: 0.032
  50. Association of Acute Gastroesophageal Reflux Disease With Esophageal Histologic Changes. JAMA. 2016 May 17; 315(19):2104-12.
    View in: PubMed
    Score: 0.031
  51. Gastroesophageal reflux disease. Current strategies for patient management. Arch Fam Med. 1996 Apr; 5(4):221-7.
    View in: PubMed
    Score: 0.031
  52. Impedance pH confirms the relationship between GERD and BMI. Dig Dis Sci. 2012 Jul; 57(7):1875-9.
    View in: PubMed
    Score: 0.023
  53. Review article: acidity and volume of the refluxate in the genesis of gastro-oesophageal reflux disease symptoms. Aliment Pharmacol Ther. 2007 May 01; 25(9):1003-17.
    View in: PubMed
    Score: 0.017
  54. The acidity index: a simple approach to the measurement of gastric acidity. Aliment Pharmacol Ther. 2004 Feb 15; 19(4):443-8.
    View in: PubMed
    Score: 0.013
  55. Health-related quality of life of patients with acute erosive reflux esophagitis. Dig Dis Sci. 1996 Nov; 41(11):2123-9.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.